2023

1. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

   Journal of medical economics, Vol. 26, Núm. 1, pp. 445-453

2. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

   BMC Pulmonary Medicine, Vol. 23, Núm. 1